Skip to content

Dott.ssa Chiaravallotti Adele

Dott.ssa Chiaravallotti Adele

Linea di ricerca:

Unità di ricerca:

Attività medica: Opera presso IRCCS Fondazione G.B. Bietti nelle sedi di Via Livenza, 3 e  Via di santo Stefano Rotondo 6, presso Presidio Ospedaliero Britannico, Roma 

Pubblicazioni scientifiche: PubMed

E-mail: adele.chiaravalloti@fondazionebietti.it

  • 26 ottobre 1999 , Laurea in Medicina e Chirurgia conseguita presso l’Università degli Studi di Roma “La Sapienza” con votazione finale di 110/110 e lode. 
  • Maggio 2000, Diploma di abilitazione alla professione di Medico-Chirurgo conseguito presso l’Università degli Studi di Roma “La Sapienza” 
  • 30 ottobre 2003, Specializzazione in Oftalmologia conseguita presso l’Università degli Studi di Roma “La Sapienza”  con votazione finale di 70/70 e lode 
  • dal 2001 , Iscrizione all’Ordine dei Medici di Roma 

 

  • Gennaio 2018 – oggi: Dirigente Medico con  contratto a tempo indeterminato  presso la Fondazione G.B.Bietti I.R.C.C.S. per lo Studio e la ricerca in Oftalmologia con attività assistenziale presso il Centro per le Maculopatie dell’Azienda Ospedaliera “Complesso Ospedaliero San Giovanni-Addolorata 
  • 2016 – 2017: Contratto di Collaborazione coordinata e continuativa presso la Fondazione G.B.Bietti I.R.C.C.S. per lo Studio e la ricerca in Oftalmologia con attività assistenziale presso il Centro per le Maculopatie dell’Azienda Ospedaliera “Complesso Ospedaliero San Giovanni-Addolorata 
  • 2015 – oggi: Contratto di lavoro a progetto presso la Fondazione G.B.Bietti I.R.C.C.S. per lo Studio e la ricerca in Oftalmologia. 
  • 1 giugno 2008 – 31 dicembre 2014:
     – Contratto di lavoro a progetto presso la Fondazione G.B.Bietti I.R.C.C.S. per lo Studio e la ricerca in Oftalmologia.
     –  Contratto di Collaborazione coordinata e continuativa presso il Centro per le Maculopatie dell’Azienda Ospedaliera “Complesso Ospedaliero San Giovanni-Addolorata 
  • Gennaio 2006 – Dicembre 2007: Borsa di Studio di ricerca per lo svolgimento di attività clinica e di ricerca nel campo della retina medica bandita dalla Fondazione G.B.Bietti I.R.C.C.S. per lo Studio e la ricerca in Oftalmologia (Reparto Retina Medica diretto dalla dott.ssa M. Varano) dove si occupa di  diagnostica mediante angiografia retinica a fluorescenza, angiografia con verde di indocianina, microperimetria con SLO e con MP1 e di terapia delle patologie corioretiniche e maculari mediante laser, terapia fotodinamica, iniezioni intravitreali di farmaci anti-VEGF. 
  • Gennaio 2004 – dicembre 2005:
    Borsa di Studio di ricerca per lo svolgimento di attività clinico-chirurgica e di ricerca nel campo della patologia vitreo-retinica bandita dalla Fondazione G.B.Bietti I.R.C.C.S. per lo Studio e la ricerca in Oftalmologia. 
  • Modificazioni retiniche funzionali e morfologiche nell’edema maculare diabetico trattato con Pegaptanib 
  • Studio in aperto della durata di 12 mesi per valutare la sicurezza e l’efficacia di ranibizumab intravitreale somministrato congiuntamente alla terapia fotodinamica con Visudyne® (PDT) in pazienti naïve con neovascolarizzazione coroideale subfoveale secondaria alla degenerazione maculare senile 
  •  Studio di 6 mesi, fase 3 , multricentrico, mascherato, randomizzato, placebo controllato (con 6 mesi di estensione in aperto) per valutare la sicurezza e l’efficacia di 700 µg e 350 µg  di dexametazone a lento rilascio (DEX PS DDS) nel trattamento dei pazienti con edema maculare conseguente a occlusione della vena centrale della retina o occlusione di branca 
  • MONTBLANC Study. A 12-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with LucentisTM versus LucentisTM monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. 
  • VIEW2 Study. A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular degeneration (AMD). 
  • DEGAS Study. A phase II prospective, randomized, multi-center, diabetic macular edema dose ranging, comparator study evaluating the efficacy and safety of PF-04523655 versus laser therapy (DEGAS). 
  • GALILEO Study. A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO). 
  • MIZAR Study. A clinical safety and efficacy comparison of NEVANAC® 0.1% to Vehicle following cataract surgery in diabetic retinopathy patients. 
  • A 12 month, phase III, randomized, double-masked, multicenter, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs verteporfin PDT in patients with visual impairment due to choroidal neovascularisation secondary to pathologic myopia. 
  • RETAIN Study. A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs 0.5 mg ranibizumab as needed in patients with macular edema and visual impairment secondary to diabetes mellitus. 
  • COMO Study. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of Ozurdex® versus Lucentis® in patients with branch retinal vein occlusion. 
  • VIVID DME Study. A randomised, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macula edema. 
  • A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema. 
  • A phase 3 randomized, double-masked, controlled trial to estblish the safety and efficacy of intravitreous administration of Fovista (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration.( Fovista-OPH1002 ) 
  • A 12- month, randomized, double-masked, sham- controlled, multicenter study to evaluate the efficacy and safety of 0,5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial qrowth factor (VEGF) driven choroidal neovascularization (CNV).MINERVA 
  • An open label randomized,active-controlled, parallel-group, Phase-3b study of the efficacy, safety,and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular de generation (nAMD)AZURE 
  • Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept – a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study (ARIES) 
  • A multi-center, single arm,interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion CENTERA 
  • Safety and efficacy of Abicipar Pegol in patients with neovascular Age-related Macular Degeneration. 
  • A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy (Fovista-OPH1004) 
  • Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients
    With Neovascular Age-related Macular Degeneration
    (SEQUOIA) 
  • One year, single arm, open label, multicenter, phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolution in wAMD patients treated with brolucizumab– IMAGINE study 
  • A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion. COMINO study 
  • A phase 3, multicenter, double-masked ,randomized study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with aflibercept ,compared with aflibercept alone, in partecipants with neovascular Age–related Macular Degeneration. COAST study 
  • Randomized,double-masked, active-controlled, phase 3 study of efficacy and safety of high dose aflibercept in patients with Neovascular Age-Related Macular Degeneration.PULSAR study 

 

  • CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, Parravano M. Retina. 2018 Jan 16. doi: 10.1097/IAE.0000000000002040. [Epub ahead of print] 
  • FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. Iacono P, Battaglia Parodi M, Selvi F, Parravano MC, Chiaravalloti A, Varano M, Bandello F. Retina. 2017 Oct;37(10):1931-1941. doi: 10.1097/IAE.0000000000001436. 
  • Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. Parravano M, Oddone F, Boccassini B, Giorno P, Chiaravalloti A, Tedeschi M, Scarinci F, Varano M. Ophthalmic Res. 2014;51(3):153-60. doi: 10.1159/000357275. Epub 2014 Mar 13. 
  • Photodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: a 10-year retrospective analysis. Varano M, Iacono P, Giorno P, Chiaravalloti A, Parravano M.
    Ophthalmologica. 2014;231(4):204-10. doi: 10.1159/000357504. Epub 2014 Jan 25. 
  • Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment.
    Parravano M, Parisi V, Ziccardi L, Chiaravalloti A, Tedeschi M, Cacciamani A, Boccassini B, Boninfante A, Varano M.
    Doc Ophthalmol. 2013 Dec;127(3):217-25. doi: 10.1007/s10633-013-9404-z. Epub 2013 Aug 13. 
  • Functional and structural assessment of lamellar macular holes. Parravano M, Oddone F, Boccassini B, Chiaravalloti A, Scarinci F, Sciamanna M, Boninfante A, Tedeschi M, Varano M.
    Br J Ophthalmol. 2013 Mar;97(3):291-6. doi: 10.1136/bjophthalmol-2011-301219. Epub 2012 Dec 19. 
  • Foveal microstructure and functional parameters in lamellar macular hole. Reibaldi M, Parravano M, Varano M, Longo A, Avitabile T, Uva MG, Zagari M, Toro M, Boscia F, Boccassini B, Chiaravalloti A, Mariotti C, Reibaldi A. Am J Ophthalmol. 2012 Dec;154(6):974-980.e1. doi: 10.1016/j.ajo.2012.06.008. Epub 2012 Sep 8. 
  • Reproducibility of macular thickness measurements using Cirrus SD-OCT in neovascular age-related macular degeneration. Parravano M, Oddone F, Boccassini B, Menchini F, Chiaravalloti A, Schiavone M, Varano M. Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4788-91. doi: 10.1167/iovs.09-4976. Epub 2010 Apr 30. 
  • Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. Parravano M, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, Varano M. Retina. 2010 Jul-Aug;30(7):1017-24. doi: 10.1097/IAE.0b013e3181cfd3c6. 
  • Choroidal neovascularization in angioid streaks and pseudoxanthoma elasticum: 1 year follow-up. Schiano Lomoriello D, Parravano MC, Chiaravalloti A, Varano M. Eur J Ophthalmol. 2009 Jan-Feb;19(1):151-3. 
  • Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. Parravano M, Oddone F, Tedeschi M, Schiano Lomoriello D, Chiaravalloti A, Ripandelli G, Varano M. Retina. 2009 Mar;29(3):329-34. doi: 10.1097/IAE.0b013e31819093e6. 
  • Posterior vitreous detachment and retinal detachment after cataract surgery. Ripandelli G, Coppé AM, Parisi V, Olzi D, Scassa C, Chiaravalloti A, Stirpe M. Ophthalmology. 2007 Apr;114(4):692-7. Epub 2007 Jan 17. 
Skip to content